Arena Pharmaceuticals to Present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
SAN DIEGO, March 29 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced that it will present a corporate update at the
CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
on Monday, April 4, 2005, at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time).
Jack Lief, President and Chief Executive Officer, will give the presentation,
which will be webcast live over the Internet. The conference will be held at
The Millennium Broadway Hotel in New York, New York.
To access the live or archived presentation, simply log on to the
following link http://www.veracast.com/webcasts/cibcwm/biotech05/31104264.cfm
or www.arenapharm.com under the investor relations section. Please connect to
either one of the websites several minutes prior to the start of the broadcast
to ensure adequate time for any software download that may be necessary. The
archived presentation will be available for 30 days on both websites.
About Arena Pharmaceuticals
Arena is a clinical-stage biopharmaceutical company focusing on the
discovery, development and commercialization of drugs in four major
therapeutic areas: metabolic, cardiovascular, inflammatory and central nervous
system diseases. Arena is developing a broad pipeline of compounds that act
on an important class of drug targets called G protein-coupled receptors, or
GPCRs, using its proprietary technologies, including CART (Constitutively
Activated Receptor Technology) and Melanophore. Arena's most advanced
clinical compound, APD356, a selective 5-HT2C serotonin receptor agonist for
the treatment of obesity, is in a Phase 2 clinical trial. Arena is also
conducting a Phase 1 clinical trial on APD125, a compound with a novel
mechanism of action (selective 5-HT2A receptor antagonist), for the treatment
of insomnia. Arena has research collaborations with Ortho-McNeil
Pharmaceutical, Inc., Merck & Co., Inc., and other companies for products in a
number of different indications.
Certain statements in this press release are forward-looking statements
that involve a number of risks and uncertainties. Such forward-looking
statements include statements about Arena's strategy, technologies,
preclinical and clinical programs, and ability to develop compounds. For such
statements, Arena claims the protection of the Private Securities Litigation
Reform Act of 1995. Actual events or results may differ materially from
Arena's expectations. Factors that could cause actual results to differ
materially from the forward-looking statements include, but are not limited
to, the timing, success and cost of Arena's research, out-licensing endeavors
and clinical studies, Arena's ability to obtain additional financing, and the
timing and receipt of payments and fees, if any, from Arena's collaborators,
including Ortho-McNeil and Merck. Additional factors that could cause actual
results to differ materially from those stated or implied by Arena's
forward-looking statements are disclosed in Arena's filings with the
Securities and Exchange Commission. These forward-looking statements
represent Arena's judgment as of the time of this release. Arena disclaims
any intent or obligation to update these forward-looking statements, other
than as may be required under applicable law.
Arena Pharmaceuticals® and Arena® are registered service marks of the
company. CART is an unregistered service mark of the company.
SOURCE Arena Pharmaceuticals, Inc.
CONTACT: Jack Lief, President and CEO of Arena Pharmaceuticals,
+1-858-453-7200, ext. 223; or Media & Investor Relations, Susan Neath of
Atkins + Associates, +1-858-527-3486, for Arena Pharmaceuticals
Web site: http://www.arenapharm.com